The impact of anti-TNF therapy on CD4+ and CD8+ cell subsets in ankylosing spondylitis
OBJECTIVES: Ankylosing spondylitis (AS) is a chronic, progressive immune-mediated inflammatory disease, driven primarily by Th1 and Th17 cells. Anti-TNF therapies are successfully used in AS to achieve and maintain remission. However, their influence on the composition of T-cell subsets is not clea...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
Karger
2018
|
| Sorozat: | PATHOBIOLOGY
85 No. 3 |
| doi: | 10.1159/000484250 |
| mtmt: | 3317419 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/13063 |
| LEADER | 02769nab a2200289 i 4500 | ||
|---|---|---|---|
| 001 | publ13063 | ||
| 005 | 20200114121034.0 | ||
| 008 | 180531s2018 hu o 0|| zxx d | ||
| 022 | |a 1015-2008 | ||
| 024 | 7 | |a 10.1159/000484250 |2 doi | |
| 024 | 7 | |a 3317419 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Dulic Sonja | |
| 245 | 1 | 4 | |a The impact of anti-TNF therapy on CD4+ and CD8+ cell subsets in ankylosing spondylitis |h [elektronikus dokumentum] / |c Dulic Sonja |
| 260 | |a Karger |c 2018 | ||
| 300 | |a 201-210 | ||
| 490 | 0 | |a PATHOBIOLOGY |v 85 No. 3 | |
| 520 | 3 | |a OBJECTIVES: Ankylosing spondylitis (AS) is a chronic, progressive immune-mediated inflammatory disease, driven primarily by Th1 and Th17 cells. Anti-TNF therapies are successfully used in AS to achieve and maintain remission. However, their influence on the composition of T-cell subsets is not clear. We aimed to characterize the changes in the T-cell repertoire after a long-term anti-TNF treatment in AS patients. METHODS: Twenty-two AS patients under long-term anti-TNF therapy were evaluated (15 anti-TNF responders and 7 nonresponders). A wide range of cell subtypes was analyzed with flow cytometry and compared with therapy-naive and short-term data too. RESULTS: Key findings include decreased proportions of naive CD4 and CD8 cells, increased frequencies of Th1 and Th17 cells and higher Th1/Th2 ratios in the long-term anti-TNF-treated patients (responders, nonresponders and total), which was found to be significant not only when compared with healthy controls, but also with therapy-naive and short-term anti-TNF-treated AS patients. We noted several alterations within the various activated T-cell subsets - increase in CD4HLADR cells in responders, in CD8HLADR cells in the whole AS group and in responders, and in CD4CD25 cells in responders, and decrease in CD4CD69 cell percentages in long-term treated patients - becoming evident only after long-term anti-TNF therapy. CONCLUSIONS: This study provides a comprehensive assessment of the impact of anti-TNF therapy on the T-cell repertoire in AS. Changes in T-cell phenotype seem to develop progressively during therapy, even in inactive disease, and reflect an ongoing effector T-cell differentiation and activation, along with the parallel compensatory increase in regulatory T cells. | |
| 700 | 0 | 1 | |a Vásárhelyi Zsófia |e aut |
| 700 | 0 | 1 | |a Bajnok Anna |e aut |
| 700 | 0 | 1 | |a Szalay Balázs |e aut |
| 700 | 0 | 1 | |a Toldi Gergely |e aut |
| 700 | 0 | 1 | |a Kovács László |e aut |
| 700 | 0 | 1 | |a Balog Attila |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/13063/1/pathobiology.pdf |z Dokumentum-elérés |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/13063/7/DulicPathophysiol2018_megjelent.pdf |z Dokumentum-elérés |